NCT02213744 (HERMIONE) (Clinical Trial/ MM-302)

Study Title
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician’s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients (HERMIONE) (NCT02213744)

Trial Description
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician’s choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.

This trial is sponsored by Merrimack Pharmaceuticals®

Study Data

  • Condition:
    • Breast Cancer
    • HER2 Positive Breast Cancer
  • Interventions:
    • Drugs used in this trial
      • MM-302
      • Gemcitabine
      • Capecitabine
      • Vinorelbine
      • Trastuzumab
  • Phase: II & III
  • Estimated Enrollment: 250
  • Start: July 2014
  • Completion: February 2017
  • Last updated: February 2016
  • Last verified: February 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: March 3, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.